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a b s t r a c t
In the current study, we have used HT-TREBS to individually analyze the DNA methylation pattern of 4799 IAP
LTR retrotransposons in embryonic stem, somatic and Neuro2A cells. According to the results, half of the loci
within this family show constant methylation patterns between the three cell types whereas the remaining
half display variable levels of methylation. About half of the variably methylated IAP LTRs tend to be
hypomethylated in ES cells, and nearly all in this group are hypomethylated in Neuro2A cells. The observed hypomethylation in both cell types occur in a non-uniform, locus-speciﬁc manner and to various degrees of
severity, with some of them being easily detectible by COBRA. Overall, this study demonstrates the feasibility
of HT-TREBS to study DNA methylation changes at retrotransposons in a locus-speciﬁc manner in multiple cell
types and further suggests the potential utility of this technique in developing epigenetic biomarkers for tracking
disease progression.
© 2014 Elsevier Inc. All rights reserved.

1. Introduction
Mammalian genomes have accumulated a large number of
retrotransposons during evolution, making up about half of the genome
in any given species [1,2]. These retrotransposons are usually repressed
by two main mechanisms. In germ cells, DNA methylation is the
major mechanism which represses the majority of retrotransposons
[3,4]. Later, in fertilized eggs, the germ cell-driven DNA methylation
is removed, and subsequently, retrotransposons are temporarily
repressed by various histone modiﬁcations [5–9]. During the implantation stage, however, these transient histone marks are again replaced
by DNA methylation, a more stable and permanent modiﬁcation. Thus,
histone modiﬁcations are usually responsible for the temporary repression of retrotransposons in transient stem cell populations whereas
DNA methylation is responsible for the more stable and permanent
repression in further committed and differentiated cell populations
[4,10,11].
It is well known that improper epigenetic regulation of
retrotransposons can result in unwanted consequences due to their
transposition [12] and their ability to inﬂuence adjacent gene activity
by acting as alternative promoters [13] or disrupting the endogenous
exon structure. The latter has been well demonstrated by the two
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cases of mouse epialleles, where the ectopic expression of two
independent IAP LTRs (Intracisternal A Particle Long Terminal Repeats)
interfere with the transcription of two endogenous loci, Avy (agouti
viable-yellow) and Axinfu (Axin-fused). In the mouse, these ectopic
expressions are responsible for visible phenotypic consequences, such
as coat color variation for Avy and tail kinkedness variations for Axinfu
[14,15]. Similar hypomethylation on retrotransposons also is seen in
cancer genomes in humans [16,17], which may result in functional
consequences in cancer progression [18,19]. However, at the same
time, hypomethylation of retrotransposons also provides a unique
opportunity for mammalian genome evolution through allowing their
co-option into the host genome as regulatory elements [20]. A recent
study suggests that endogenous retroviruses (ERVs) in the human
genome may have played an important role in the evolution of the
central nervous system by affecting gene expression in key areas of
the brain [21]. Overall, DNA methylation at retrotransposons is not
only of interest toward understanding complex human disorders with
an epigenetic underpinning, including cancers [22,23], but also for
their role in shaping mammalian evolution.
Given the importance of epigenetic modiﬁcations on retrotransposons, much research is currently focused on understanding the
extent to which they are repressed in normal as well as diseased cells
and tissues. However, due to the paucity of methods allowing for deep
sequencing coverage at repeat elements and ﬂanking loci, it has thus
far been difﬁcult to perform a systematic analysis of the effect of DNA
methylation at individual loci in a locus-speciﬁc manner. To address
these issues, we have developed a new protocol termed HT-TREBS
(High-Throughput Targeted Repeat Element Bisulﬁte Sequencing) [24],
which is designed to survey the DNA methylation levels of a large
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number of interspersed repeat elements on an individual-locus basis.
According to the results from a set of pilot experiments analyzing
mouse IAP LTRs, the majority of this retrotransposon family is properly
repressed in normal cells, but a very small number of IAP LTRs (about
5%) escape this repression mechanism [24,25]. In the current study,
this protocol has been utilized to characterize the DNA methylation
proﬁle of this retrotransposon family in AB2.2 embryonic stem and
Neuro2A cancer cells and subsequently compared with the somatic
cell data derived from Ekram and Kim [24]. The results revealed that
the DNA methylation levels of a large fraction of IAP LTRs, though not
all, are dynamically ﬂuctuating between different cell types, with
some of them being easily detectible by quick methods such as
COBRA. Overall, these analyses demonstrate the feasibility of using
HT-TREBS to ﬁnd potential epigenetic biomarkers of cell state in
multiple different cell types.
2. Results
2.1. HT-TREBS analyses of IAP LTRs in ES, somatic and Neuro2A cells
In the current study, we analyzed and compared the DNA methylation levels of the IAP LTR family using the following three cell types:
embryonic stem (ES), somatic and Neuro2A cancer cells. Genomic
DNA isolated from ES cells (AB2.2 cell, 129 origin, from Baylor College
of Medicine) and a neuroblastoma cell line of strain A origin (Neuro2A)
were treated according to an established protocol of HT-TREBS [24]. In
brief, the genomic DNA was fractionated by sonication, ligated to an
adaptor and modiﬁed with bisulﬁte conversion protocol [26]. It was
then ampliﬁed with a PCR scheme designed to enrich IAP LTRgenomic regions. This was accomplished by designing one of the
primers complementary to the 24-bp portion within the U3 region of
the LTR that is conserved between ﬁve subtypes of IAP LTR (IAPLTR1,
IAPLTR1a, IAPLTR2, IAPLTR2a, and IAPLTR2b), and is devoid of any CG
dinucleotides. The region is located approximately 150 bp downstream
of TGTTGGG (denoting the extreme 5′ end of the LTR), and includes the
CAT box. The ampliﬁed library was ﬁnally size-fractionated with
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agarose gel electrophoresis. The prepared libraries were sequenced
with a Next-Generation-Sequencing (NGS) protocol.
We have obtained 6.3 and 6.8 million raw sequence reads from
ES and Neuro2A cells, respectively. Each set of bisulﬁte-converted
sequence reads was mapped and processed to derive the methylation
level of each IAP LTR locus as described below. In brief, individual raw
sequence reads were mapped to a custom database containing the
sequences of about 10,000 IAP LTR loci. In this database, each locus is
represented with a 1030-bp sequence covering the 330-bp LTR plus
two 350-bp ﬂanking regions. A set of sequence reads mapped to a
given locus was subsequently used for calculating its methylation
level. We have successfully obtained the methylation values for 5637
and 5575 loci of IAP LTRs for ES and Neuro2A cells respectively. In
both sets, 100 mapped raw sequences were used on average to derive
methylation level of each IAP LTR locus, covering an average of 7 CpG
sites per locus. Next, these two new data sets were compared with the
somatic data set representing the average methylation values of IAP
LTRs that were individually derived from the three organs (brain, liver
and kidney) of a two-month-old C57BL/6N mouse (Fig. 1) as well as
to the data sets derived from each of the organs representing the
three tissue layers individually [24]. According to our analyses with
the individual tissues (Supplemental Fig. 1), the liver and kidney
showed overall more similarity in DNA methylation levels between
each other than with the brain. However, on the whole, over 95% of all
IAP LTRs were methylated at similar levels in all three organs, as
observed by Ekram and Kim [24]. Therefore, in order to compare ES
and Neuro2A cells to a representative DNA methylation value in normal
somatic cells, all further analyses were performed with the average
somatic data set. Finally, the three data sets (ES, somatic and Neuro2A)
were compiled to derive 4799 IAP LTRs with a minimum of 15×
coverage at each CpG site that were represented in all three cell types
for further comparisons (Supplemental Data 1 and Fig. 1).
Initial tabulation of these data sets revealed the following immediate
conclusions. The overall DNA methylation levels of IAP LTRs are variable
among the three samples: the DNA methylation levels in somatic cells
are the highest, followed by ES and Neuro2A cells, as was indicated by

Fig. 1. HT-TREBS analyses of IAP LTRs in ES, somatic and Neuro2A cells. (A) COBRA analyses of the IAP LTRs in ES, somatic and Neuro2A cells. The bisulﬁte-treated DNA was ampliﬁed with a
primer set targeting the entire family of this retrotransposon. Restriction enzymes recognizing methylated CpG (TaqαI and HpyCH4IV) as well as unmethylated CpG dinucleotides after
bisulﬁte treatment and PCR (FokI) indicate hypomethylation in Neuro2A cells compared to ES and somatic (brain) cells. Expected DNA fragment sizes based on CpG methylation status
are marked by “U” (unmethylated) or “M” (methylated). The no-enzyme control for each restriction digestion is indicated by a minus sign. (B) The entire set of 4799 IAP LTRs in each
cell type was ﬁrst grouped into different bins based on their methylation levels, and subsequently presented as a line graph. A series of bins on X-axis represent a gradual increment of
DNA methylation from 0 to 100% whereas the values on Y-axis represent the number of IAP LTRs in each bin. All IAP LTRs methylated under 80% (left of the dotted line) were considered
hypomethylated. The actual tabulated numbers of IAP LTRs in each bin for the three cell types are also presented as a table (C).
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the result of COBRA (COmbined Bisulﬁte Restriction Analysis [27]),
showing a substantial level of DNA hypomethylation in Neuro2A
cells as compared to the much greater levels of DNA methylation
in both ES and somatic cells (Fig. 1A). Next, in order to quantify the
level of DNA methylation difference, the set of 4799 loci was divided
into two groups: hypermethylated (≥ 80% methylation level) and
hypomethylated (b80% methylation level). IAP LTRs methylated above
80% showed no major differences among them, whereas those under
80% methylation level showed some unique patterns of hypomethylation, as discussed previously by Ekram and Kim [24]. The same was
largely true for thresholds under 80% (70–75%), however the number
of loci in the hypomethylated category was too few for meaningful
comparisons with the hypermethylated category under these
conditions. Therefore, the empirically selected 80% threshold, which is
consistent with that established by Ekram and Kim [24], ensured an
adequate number of loci in each group while staying close to the base
of the curve shown in Fig.1B. According to the results, about 96%
of IAP LTRs (4587 loci) showed at least 80% methylation level in
somatic cells whereas only 77% (3689 loci) and 51% (2465 loci) were
hypermethylated in ES and Neuro2A cells respectively (Fig. 1BC). In
somatic cells, only 4% of the loci (212 IAP LTRs) belonged to the
hypomethylated category, while 23% of IAP LTRs (1110 loci) and nearly
half (2334 loci) showed less than 80% methylation levels in ES and
Neuro2A cells respectively (Fig. 1BC). Overall, these initial analyses
demonstrate the severe hypomethylation of IAP LTR loci in Neuro2A
cells which is in stark contrast with the much higher levels of methylation seen in ES and somatic cells.
2.2. Comparative analyses of DNA methylation proﬁles in ES and Neuro2A
vs. somatic cells
The DNA methylation pattern of each individual IAP LTR locus in ES
and Neuro2A cells was analyzed in comparison to somatic cells using a
two-dimensional dot plot display (Fig. 2). In a given plot, each dot represents one IAP LTR with two values: X- and Y-axis values representing
DNA methylation levels derived from two comparing cell types. As
shown in Fig. 2A, the majority of dots (IAP LTRs) are located within
the 80–100% methylation range in both ES and somatic cells. Yet, a
substantial fraction of IAP LTRs are spread horizontally over the methylation ranges less than 80% in ES cells but still greater than 80% in somatic
cells. In terms of actual number, this group is estimated to contain
around 932 IAP LTRs based on the initial tabulation (Fig. 1C). A small
number of IAP LTRs also show even greater degrees of DNA methylation

difference between ES and somatic cells based on their location in the
upper left corner of the dot plot where the DNA methylation levels are
less than 40% in ES but greater than 80% in somatic cells. Another set
of IAP LTRs is located along the diagonal line connecting the lower left
to upper right corner. These dots belong to the group of IAP LTRs
showing hypomethylation regardless of cell type, whose methylation
values, interestingly enough, are also known to be variable between
different individuals [24,25]. Overall, this dot plot analysis highlights
the observation that a large portion of IAP LTRs are hypomethylated in
ES cells but not in somatic cells (Fig. 2A).
Comparing DNA methylation patterns of IAP LTRs in Neuro2A and
somatic cells (Fig. 2B) indicates that a much greater number of IAP
LTRs, around 2152 elements, show different levels of methylation
between the two cell types. A majority of these loci (2137 elements),
represented by a large number of dots spreading horizontally to the
left from the upper right corner in the dot plot, show greater than 80%
methylation in somatic cells but less than 80% methylation in Neuro2A
cells. It is interesting to note that all the individual IAP LTRs of this
group have different levels of DNA methylation change: some have
much greater levels, such as the ones in the top left corner which
are nearly completely methylated in somatic cells but completely
unmethylated in Neuro2A cells, whereas others have more modest
levels of change. This individuality of DNA methylation change is even
more contrasting in the case of the other remaining half of the IAP
LTRs, which still show similar levels of DNA methylation between
somatic and Neuro2A cells. Overall, this analysis indicates that about
half, but not all, of the IAP LTRs are hypomethylated in Neuro2A
compared to somatic cells. Given all the different degrees and the
various patterns of changes, the observed methylation difference
between the two cell types is thought to be locus-speciﬁc rather than
uniform, which may be reﬂecting the fact that not all IAP LTRs are
equally sensitive to cell type in terms of their DNA methylation.
2.3. DNA methylation pattern-based grouping of IAP LTRs
The various different methylation levels of each individual IAP LTR in
the three different cell types were further studied by Venn diagram
analysis using Venny [28]. In this analysis, each IAP LTR has one of the
two states in a given cell type, either High (≥ 80%) or Low (b 80%)
level of methylation based on the division established from Fig. 1BC.
Since each IAP LTR is present in three different cell types, ES, somatic
and Neuro2A, eight different combinations of DNA methylation states
are possible for any given IAP LTR (Fig. 3). The ﬁrst Venn diagram was

Fig. 2. DNA methylation proﬁles of IAP LTRs in ES and Neuro2A cells compared to somatic cells. The methylation levels of IAP LTRs were compared between ES and somatic cells (A) and
between somatic and Neuro2A cells (B). For both scatter plot analyses, each given dot represents one IAP LTR, and the position of the dot (on the X and Y plane) indicates the methylation
levels from the two cell types that are being compared. The dots spreading horizontally toward the left on the ﬁrst plot indicates that a substantial fraction of IAP LTRs is hypomethylated in
ES cells but not in somatic cells. Similarly, a large number of dots spreading horizontally to the left from the right corner of the second graph represent the hypomethylation of half of IAP
LTRs in Neuro2A cells, but their methylation levels are still greater than 80% in somatic cells.
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Fig. 3. DNA methylation pattern-based grouping of IAP LTRs. A given IAP LTR has one of two states, either Low (b80% methylation) or High (≥80% methylation) in each of the three cell
types, resulting in eight total possible categories of DNA methylation patterns. The ﬁrst Venn diagram was constructed through comparing the three sets of IAP LTRs showing less than 80%
methylation level (Low) in the three cell types (A). The second Venn diagram was derived from comparing the three sets of IAP LTRs with their methylation levels being at least 80% (B).
The resulting eight different categories of IAP LTRs are presented along with the actual numbers of loci in (C).

constructed through comparing three sets of IAP LTRs that show less
than 80% methylation level in all three cell types (Fig. 3A). This, subsequently, derived seven groups of IAP LTRs, which are represented by
the seven small sections of the ﬁrst Venn diagram. The three nonoverlapping sections indicate the three groups with one Low state in
the three different cell types (LHH, HLH, HHL in Fig. 3C), whereas the
three overlapping sections between two cell types (or circles) indicate
the groups with two Low states (LLH, LHL, HLL). One remaining group
is overlapped by three Low states (LLL), meaning that this group of
IAP LTRs maintains Low methylation in all three cell types. One ﬁnal
group is missing in the ﬁrst Venn diagram, but is found in the center
section of the second Venn diagram that has been constructed with
the three sets of IAP LTRs showing greater than 80% methylation level.
The ﬁnal group of IAP LTRs is characterized by greater than 80%
methylation levels in all three different cell types (HHH) (Fig. 3B).
The actual numbers of IAP LTRs constituting each of the eight groups
are summarized in Fig. 3C. According to this summary, there are three
groups which are represented by very small numbers of IAP LTRs,
which include LLH (11), HLL (30) and HLH (4). Of the remaining ﬁve
groups, two of them, LLL (167) and HHH (2257), show constant DNA
methylation and make up 3.5 and 47% of the entire IAP LTR family,
respectively. The other three groups with ﬂuctuating methylation levels
altogether make up the remaining half: the HHL group (29%, 1398
members), the LHL group (15%, 739 members) and the LHH group
(4%, 193 members).
These IAP LTRs within these Venn diagram groups were further
analyzed in order to ascertain any biological signiﬁcance behind the
various patterns of methylation observed for these IAP LTRs. They
were studied with regards to expressed sequence tags (ESTs), histone
modiﬁcations (data not shown), gene association and genomic position
preference along with the 20 kb ﬂanking sequence in order to survey a
representative portion of the mouse genome covered by the IAP LTRs
(Supplemental Fig. 2). No speciﬁc epigenetic mark distinguished any
one of the groups from others. IAP LTRs within all groups were associated
with 0–2 genes, albeit only distally, with most IAP LTRs being positioned
within 50–500 kb of transcription start sites (TSS) (Supplemental

Fig. 2AB) as previously observed by Ekram and Kim [24]. There was
no genomic location preference observed for any these groups of IAP
LTRs with respect to their chromosomal location or distance to TSS
(Supplemental Fig. 2BC) which distinguished them from each other,
after accounting for the large variation in sample sizes. In summary,
according to this series of Venn diagram analyses, the DNA methylation
levels of half of the IAP LTRs are static and constant whereas the
remaining half ﬂuctuates between different cell types without any
gene association or chromosomal position preference.
2.4. COBRA analyses of representative IAP LTR loci
We employed COBRA as an independent method of assessing DNA
methylation at some of the loci representing the various Venn diagram
groups. It provided us with a rapid view of the differences between cell
types through testing the methylation level associated with 1–3 CpG
sites associated with the retrotransposon. Bisulﬁte-treated brain DNA
was chosen as a representative organ for somatic cells.
One representative example of COBRA analysis of the locus
IAPLTR1a_Mm-ERVK-LTR chrX: 39388013-39388339, associated distally
with the gene Xiap, is shown along with the corresponding HT-TREBS
data set (Fig. 4A). The black triangles over the heatmaps indicate one
of the two HpyCH4IV restriction sites in the ampliﬁed portion of the
IAP LTR which was also sequenced by HT-TREBS. This particular CpG
site was methylated in 133 reads out of a total of 191 reads in ES cells
(70% methylation), 89 out of 137 in the brain (65% methylation) and 0
out of 187 reads (0% methylation) in Neuro2A cells. The stark difference
in methylation states at this position between Neuro2A, and ES and
somatic cells, is clearly demonstrated by the COBRA which shows an
undigested DNA fragment for Neuro2A whereas complete digestion is
observed for the ES and somatic cell samples.
COBRA results of four other loci from various different groups are
shown in Fig. 4B. A full description of each of these loci, along with the
gene they are associated with, may be found in Supplemental Data 2.
It becomes apparent from these COBRA analyses that the difference in
methylation level between Neuro2A and other cell types at the tested
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Fig. 4. COBRA analyses of representative IAP LTR loci. (A) Representative COBRA analysis shown along with heatmaps from HT-TREBS analysis. Red boxes indicate methylated CpG sites
and blue boxes indicate unmethylated CpG sites in the heatmaps in the bottom panel, with a blank box indicating insufﬁcient sequencing coverage. Black triangles indicate one of the
restriction sites, which was also sequenced by HT-TREBS. (B) COBRA analysis from four randomly chosen loci representing the various Venn diagram groups. All loci in (A) and (B) are
named after the gene they are (distally) associated with and the Venn diagram group they belong to. A full description of each locus may be found in Supplemental Data 2. The percent
numbers shown under the images indicate the average methylation level of this locus in the indicated cell type. The expected fragments sizes following the restriction enzyme digestion as
indicated are marked by “U” (unmethylated) or “M” (methylated) based on the CpG site methylation status. The no-enzyme control for each restriction digestion is indicated by a minus
sign.

CpG sites are greater at some IAP LTRs compared to others. Two of
the loci presented in this panel (IAP LTRs associated with Fos and
Tcam1) show severe hypomethylation in Neuro2A cells, such that the
undigested DNA fragments are easily detectible by COBRA. In contrast,
the IAP LTR located within the second intron of Itpk1 shows marked
hypermethylation in Neuro2A, but much lower levels of methylation
in ES and somatic cells. In general, these results are consistent with
the detailed DNA methylation data obtained from these loci through
HT-TREBS. However, not all loci can be tested as easily using COBRA
due to technical limitations, such as low sensitivity and resolution
capacity, as seen in the case of the IAP LTR associated with Aebp2. In
conclusion, this set of analyses demonstrates that the DNA methylation
difference at certain loci, though not all, could be veriﬁed using an
independent method, COBRA.
3. Discussion
In the current study, the DNA methylation patterns of the mouse
retrotransposon family IAP LTR have been studied in three distinct
cell types: embryonic stem (ES), somatic and a neuroblastoma
cell line, Neuro2A (Fig. 1). Previous studies on DNA methylation of
retrotransposons have focused on analyzing them as an entire group,
without regard for locus-speciﬁc variations in methylation patterns.
Therefore, thus far, it was unclear whether all loci behaved similarly in
different cell types or whether some were more susceptible to changes
in DNA methylation levels based on cell type and stage. Using HT-TREBS
[24], we have now been able to analyze retrotransposons for the ﬁrst
time in a locus-speciﬁc manner, which has revealed its non-uniform
nature of hypomethylation in ES and Neuro2A cells (Fig. 2). The results
suggest that not all IAP LTRs are equally sensitive to cell types and stages
in terms of their DNA methylation level. Certain IAP LTRs showed severe
hypomethylation in ES and Neuro2A cells, while others were stably
methylated at either high or low levels (Figs. 3 and 4). Interestingly,
much greater levels of hypomethylation were observed in Neuro2A
cells than in ES cells, which may be due to two reasons. First, it may
be due to strain related differences between strain A, 129 and C57BL/
6N or cell line related artifacts which are not relevant in vivo. Second,
Neuro2A cell line is derived from a murine neuroblastoma and hence
is likely to show some cancer related signatures. From this perspective,
the severe DNA hypomethylation of Neuro2A cells is consistent
with various other reports about genome-wide hypomethylation of

retrotransposons in cancer cells [17,18,29–32]. According to the current
study, however, it is apparent that not all retrotransposons are likely
to behave in a similar fashion when a cell undergoes transformations
such as in development or cancer. Only a subset of all loci are likely to
undergo changes in DNA methylation in response to such stresses,
with varying degrees of severity depending upon the locus.
The hypomethylation we observed in ES cells had also been
previously predicted based on the propensity for temporary silencing
marks in these transient cell populations, even on retrotransposons [5,
6]. In fact, a recent whole-genome bisulﬁte sequencing analysis by
Stadler et al. [33] showed that repeat elements comprised approximately
34% of all “low-methylation regions” (55–75% methylation) and 7% of all
“unmethylated regions” (b55% methylation). The scope of this study,
however, does not allow it to focus on the composition of the repeat
elements analyzed within these under-methylated groups. Here we
show with greater speciﬁcity and sequencing depth for IAP LTR
retrotransposons that 25% of the loci tend to be hypomethylated
(b80% methylation level) in these 129-derived ES cells. Such levels of
hypomethylation in ES cells, however, is not a sign of increased
transcriptional activity since only 0.23% of all ESTs in a blastocyst are
associated with IAP elements [34]. Furthermore, Dnmt1-deﬁcient ES
cells are only found to overexpress IAP mRNA upon differentiation
and not in their pluripotent state [11]. This apparent paradox is
explained by recent studies which have shown that KAP1, SETDB1
and HP1 act in tandem to silence retrotransposons in a DNA
methylation-independent manner through H3K9 trimethylation in ES
cells [7–9]. These temporary, but strong, silencing histone marks sustain
proper repression while still allowing a signiﬁcant fraction of the
retrotransposons to remain hypomethylated. A subset of these
hypomethylated retrotransposons then have the opportunity to
become co-opted into the host genome as regulatory elements.
Instances of such adaptation of retrotransposons have been previously
observed in ES cells [35,36] as well as other tissues [21,37] in both
humans and mice. It is possible, then, that a small fraction of the 1110
hypomethylated IAP LTRs detected in this study may also function as
regulatory elements for nearby genic regions, much as the stem cellrelated promoters and enhancers originating from ERVs that were
recently identiﬁed by Fort et al. [35].
In conclusion, through this study, we have been able to demonstrate
the feasibility of using HT-TREBS as a Next-Generation-Sequencing
based approach to reliably assess the DNA methylation levels of
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retrotransposons in multiple different cell types. With greater speciﬁcity
for targeted repeat elements and deep sequencing coverage, HT-TREBS
may be used for identifying those retrotransposons which may be
important for genome evolution or be associated with disease states
in humans as well as mice. For instance, our observations in Neuro2A
cells (Fig. 2), which are potentially cancer-like, allow us to predict that
only a subset of retrotransposons are likely to suffer from hypomethylation in most cancers with some facing much greater levels of demethylation compared to other loci. Moreover, based on the heterogeneity of
cancer, it is predicted that the loci facing hypomethylation will most
likely be different based on the origin of the tumor and to different
degrees depending on the locus. HT-TREBS can be employed on a
large-scale basis to test which retrotransposons suffer hypomethylation
and to what levels in different types of cancers. Since certain loci are
likely to be severely hypomethylated, such as the ones demonstrated
in Fig. 4, they can be easily and quickly detected by COBRA and
used as cancer biomarkers. Furthermore, given that certain loci are
hypomethylated at extreme levels in Neuro2A cells (0–5% methylation), it is possible that demethylation events at these IAP LTRs are
additive over time. If one may indeed consider Neuro2A cells to be
somewhat reﬂective of a neuroblastoma cell state, this could indicate
that certain speciﬁc retrotransposable loci may start losing methylation
very early during tumorigenesis events. Such loci, as biomarkers,
could be useful for tracking cancer progression. The sensitivity of HTTREBS also provides us with the opportunity to ﬁnd the subset of
retrotransposons which are potentially associated with tumor suppressors or oncogenes and can affect their expression patterns, since early
demethylation at these loci could indicate their status as drivers of
cancer progression. Overall, the various different patterns of DNA
hypomethylation observed in ES and Neuro2A cells via HT-TREBS,
in this study, introduce the possibility of identifying speciﬁc repeat
elements which may serve as biomarkers for different cell states and
be especially useful for tracking disease progression.
4. Materials and methods
4.1. HT-TREBS analyses of DNA isolated from ES and Neuro2A cells
For the current study, the HT-TREBS protocol developed and
employed by Ekram and Kim to characterize somatic tissues (brain,
liver and kidney) from a two-month-old C57BL/6N mouse [24] was
applied to ES (AB2.2 from Baylor College of Medicine) and Neuro2A
cells. For each sample, 1 μg of the puriﬁed genomic DNA was fragmented
with sonication (Bioruptor NGS, Diagenode) to generate a pool of DNA
fragments with the peak size being around 700 bp in length. The
fragmented DNA was end-repaired using the NEBNext® End Repair
Module (New England BioLabs), and ligated to custom-made Ion
Torrent ‘A’ adaptors in which all the cytosines have been methylated
(Integrated DNA Technologies). The adaptor-ligated DNA fragments
were further size-selected to remove any excess adaptors and DNA
fragments smaller than 300 bp in length using the Agencourt AMPure
XP beads (Beckman Coulter). The adaptor-ligated DNA library was
modiﬁed using the bisulﬁte conversion reaction according to the
manufacturer's protocol (EZ DNA Methylation™ kit, Zymo Research).
The bisulﬁte-converted library was used as template for a round of
PCR (Maxime PCR Premix Kit, Intron Biotech) using the following two
primers: the forward primer (5′-CCATCTCATCCCTGCGTGTCTCCGACTC
AG-3′) designed to bind to the 5′ end of the ‘A’ adaptor region and the
reverse primer (5′-CCACTACGCCTCCGCTTTCCTCTCTATGGGCAG TCGG
TGAT^CTCCCTAATTAACTACAACCCATC-3′) designed to bind to the
24-bp region that is well conserved among the IAP LTR subtypes (IAP
LTR1, 1a, 2, 2a, and 2b). The sequence in the 5′-side of the reverse
primer marked by ^ corresponds to the ‘P1’ adaptor, which is part of
the ampliﬁcation strategy used for the Ion Torrent NGS scheme (Ion
Torrent, Life Technologies). The PCR product was ﬁnally size-selected
for a range of 250–300 bp in length using agarose gel electrophoresis.
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Each of the two PCR products was then individually sequenced in the
Ion Personal Genome Machine (PGM) Sequencer using Ion 318 Chips
(Ion Torrent, Life Technologies). The sequence reads generated from
the two Ion PGM runs were individually mapped using the aligner
Bowtie2 [38] to a curated reference genome made up of bisulﬁteconverted IAP LTR sequences. The mapped reads were ﬁltered through
several custom Perl scripts to extract only the sequences covering the
IAP LTR and ﬂanking unique regions. The ﬁltered reads from each
sample were separately analyzed using the BiQAnalyzerHT tool [39].
The detailed information regarding Perl scripts and bioinformatic
pipelines are available upon request. ES and Neuro2A datasets have
been added to the NCBI's Gene Expression Omnibus [40] data repository
and can be viewed under the accession number GSE60007 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60007).
4.2. COBRA analyses
Approximately 500 ng of puriﬁed genomic DNA from AB2.2 ES
cell, Neuro2A and C57BL/6N brain was treated using the EZ DNA
Methylation™ kit according to the manufacturer's protocol (Zymo
Research). This bisulﬁte-treated DNA was then used for the COBRA
(COmbined Bisulﬁte Restriction Assay) analyses. Speciﬁcally, 1 μL
(~ 20 ng) of the converted DNA was used for methylation-unbiased
PCR (Maxime PCR Premix Kit, Intron Biotech) using bisulﬁte primers
which lacked any CpG dinucleotides or cytosines (all cytosines were
converted to thymines). Next, ampliﬁed DNA was digested using appropriate restriction enzymes which recognized at least one CpG site as
part of their recognition sequence (New England BioLabs). All primers,
PCR conditions and ampliﬁed region coordinates (according to the
mm9 version of the mouse genome) may be found in Supplemental
Data 2, along with the restriction enzymes used for COBRA.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygeno.2014.09.009.
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